Valuation: NIOX Group Plc

Capitalization 263M 353M 304M 274M 480M 32.4B 502M 3.24B 1.3B 15.54B 1.32B 1.3B 55.57B P/E ratio 2025 *
32.6x
P/E ratio 2026 * 29.5x
Enterprise value 244M 327M 282M 255M 445M 30.05B 466M 3.01B 1.21B 14.41B 1.23B 1.2B 51.55B EV / Sales 2025 *
5.01x
EV / Sales 2026 * 4.64x
Free-Float
55.67%
Yield 2025 *
2.16%
Yield 2026 * 2.4%
1 day-0.94%
1 week-3.08%
Current month-3.08%
1 month-4.55%
3 months-10.26%
6 months-14.63%
Current year-5.12%
1 week 63
Extreme 63
66
1 month 62.4
Extreme 62.4
67.8
Current year 62.4
Extreme 62.4
71
1 year 53.4
Extreme 53.4
77.6
3 years 42.3
Extreme 42.3
80
5 years 24.8
Extreme 24.8
80
10 years 12.5
Extreme 12.5
283.6
Manager TitleAgeSince
Chief Executive Officer - 15/01/2025
Director of Finance/CFO - 13/05/2025
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 58 07/02/2018
Director/Board Member - 01/09/2019
Chairman 73 04/12/2019
Change 5d. change 1-year change 3-years change Capi.($)
-0.94%-3.08%-1.87%+28.57% 353M
+0.72%-5.86%+8.50%+210.49% 885B
+0.32%-3.23%+44.97%+54.54% 579B
-0.96%-0.85%+9.19%+48.19% 407B
-2.93%-7.03%+12.72%+26.04% 350B
-1.25%-5.55%+23.92%+55.59% 302B
-1.85%-6.70%+20.55%+34.98% 301B
-0.24%-6.49%+23.18%+4.22% 286B
+0.53%-4.80%+16.27%+57.17% 199B
-0.83%-3.37%+24.03%+77.45% 179B
Average -0.74%-4.53%+18.15%+59.73% 348.91B
Weighted average by Cap. -0.47%-4.59%+19.88%+86.08%

Financials

2025 *2026 *
Net sales 48.71M 65.22M 56.23M 50.76M 88.82M 5.99B 92.95M 600M 240M 2.87B 245M 240M 10.28B 50.53M 67.66M 58.34M 52.66M 92.14M 6.22B 96.43M 623M 249M 2.98B 254M 249M 10.66B
Net income 11.46M 15.35M 13.24M 11.95M 20.9M 1.41B 21.88M 141M 56.58M 677M 57.61M 56.38M 2.42B 14.08M 18.85M 16.25M 14.67M 25.67M 1.73B 26.86M 173M 69.47M 831M 70.74M 69.23M 2.97B
Net Debt -19.07M -25.54M -22.02M -19.88M -34.78M -2.35B -36.4M -235M -94.13M -1.13B -95.84M -93.8M -4.03B -28.83M -38.6M -33.28M -30.04M -52.56M -3.55B -55.01M -355M -142M -1.7B -145M -142M -6.08B
Logo NIOX Group Plc
NIOX Group plc is a United Kingdom-based diagnostics and management company that is focused on asthma. The Company is engaged in the design, development, and commercialization of medical devices for the measurement of fractional exhaled nitric oxide (FeNO), a precise biomarker for asthma. The Company's NIOX FeNO measurement and monitoring products are used by physicians around the globe to help improve asthma diagnosis and management. The Company offers NIOX VERO, a point of care device for the accurate measurement of nitric oxide (NO) as a biomarker of airway inflammation to help diagnose and manage asthma. The device is used by healthcare professionals to improve asthma care, which assists diagnosis, determining responsiveness to inhaled corticosteroids, tailoring inhaled steroid use, monitoring treatment compliance, and reducing the likelihood of exacerbations in at-risk patients compared to traditional monitoring. The Company offers products and services in around 50 countries.
Employees
91
Date Price Change Volume
06/03/26 63.00 p -0.94% 317,666
05/03/26 63.60 p 0.00% 231,040
04/03/26 63.60 p -0.31% 836,471
03/03/26 63.80 p -0.31% 1,056,008
02/03/26 64.00 p -1.54% 561,917
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
0.6300GBP
Average target price
0.8340GBP
Spread / Average Target
+32.38%

Annual profits - Rate of surprise